Tags

Type your tag names separated by a space and hit enter

p-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis.
Korean J Pediatr. 2013 Apr; 56(4):159-64.KJ

Abstract

PURPOSE

Indoxyl sulfate and p-cresyl sulfate are important protein-bound uremic retention solutes whose levels can be partially reduced by renal replacement therapy. These solutes originate from intestinal bacterial protein fermentation and are associated with cardiovascular outcomes and chronic kidney disease progression. The aims of this study were to investigate the levels of indoxyl sulfate and p-cresyl sulfate as well as the effect of probiotics on reducing the levels of uremic toxins in pediatric patients on dialysis.

METHODS

We enrolled 20 pediatric patients undergoing chronic dialysis; 16 patients completed the study. The patients underwent a 12-week regimen of VSL#3, a high-concentration probiotic preparation, and the serum levels of indoxyl sulfate and p-cresyl sulfate were measured before treatment and at 4, 8, and 12 weeks after the regimen by using fluorescence liquid chromatography. To assess the normal range of indoxyl sulfate and p-cresyl sulfate we enrolled the 16 children with normal glomerular filtration rate who had visited an outpatient clinic for asymptomatic microscopic hematuria that had been detected by a school screening in August 2011.

RESULTS

The baseline serum levels of indoxyl sulfate and p-cresyl sulfate in the patients on chronic dialysis were significantly higher than those in the children with microscopic hematuria. The baseline serum levels of p-cresyl sulfate in the peritoneal dialysis group were significantly higher than those in the hemodialysis group. There were no significant changes in the levels of these uremic solutes after 12-week VSL#3 treatment in the patients on chronic dialysis.

CONCLUSION

The levels of the uremic toxins p-cresyl sulfate and indoxyl sulfate are highly elevated in pediatric patients on dialysis, but there was no significant effect by probiotics on the reduction of uremic toxins in pediatric dialysis patients. Therefore, studies for other medical intervention to reduce uremic toxins are also necessary in pediatric patients on dialysis.

Authors+Show Affiliations

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23646054

Citation

Hyun, Hye Sun, et al. "P-Cresyl Sulfate and Indoxyl Sulfate in Pediatric Patients On Chronic Dialysis." Korean Journal of Pediatrics, vol. 56, no. 4, 2013, pp. 159-64.
Hyun HS, Paik KH, Cho HY. P-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis. Korean J Pediatr. 2013;56(4):159-64.
Hyun, H. S., Paik, K. H., & Cho, H. Y. (2013). P-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis. Korean Journal of Pediatrics, 56(4), 159-64. https://doi.org/10.3345/kjp.2013.56.4.159
Hyun HS, Paik KH, Cho HY. P-Cresyl Sulfate and Indoxyl Sulfate in Pediatric Patients On Chronic Dialysis. Korean J Pediatr. 2013;56(4):159-64. PubMed PMID: 23646054.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - p-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis. AU - Hyun,Hye Sun, AU - Paik,Kyung Hoon, AU - Cho,Hee Yeon, Y1 - 2013/04/22/ PY - 2012/09/10/received PY - 2012/10/09/revised PY - 2012/10/24/accepted PY - 2013/5/7/entrez PY - 2013/5/7/pubmed PY - 2013/5/7/medline KW - Children KW - Chronic dialysis KW - Indoxyl sulfate KW - Probiotics KW - p-Cresyl sulfate SP - 159 EP - 64 JF - Korean journal of pediatrics JO - Korean J Pediatr VL - 56 IS - 4 N2 - PURPOSE: Indoxyl sulfate and p-cresyl sulfate are important protein-bound uremic retention solutes whose levels can be partially reduced by renal replacement therapy. These solutes originate from intestinal bacterial protein fermentation and are associated with cardiovascular outcomes and chronic kidney disease progression. The aims of this study were to investigate the levels of indoxyl sulfate and p-cresyl sulfate as well as the effect of probiotics on reducing the levels of uremic toxins in pediatric patients on dialysis. METHODS: We enrolled 20 pediatric patients undergoing chronic dialysis; 16 patients completed the study. The patients underwent a 12-week regimen of VSL#3, a high-concentration probiotic preparation, and the serum levels of indoxyl sulfate and p-cresyl sulfate were measured before treatment and at 4, 8, and 12 weeks after the regimen by using fluorescence liquid chromatography. To assess the normal range of indoxyl sulfate and p-cresyl sulfate we enrolled the 16 children with normal glomerular filtration rate who had visited an outpatient clinic for asymptomatic microscopic hematuria that had been detected by a school screening in August 2011. RESULTS: The baseline serum levels of indoxyl sulfate and p-cresyl sulfate in the patients on chronic dialysis were significantly higher than those in the children with microscopic hematuria. The baseline serum levels of p-cresyl sulfate in the peritoneal dialysis group were significantly higher than those in the hemodialysis group. There were no significant changes in the levels of these uremic solutes after 12-week VSL#3 treatment in the patients on chronic dialysis. CONCLUSION: The levels of the uremic toxins p-cresyl sulfate and indoxyl sulfate are highly elevated in pediatric patients on dialysis, but there was no significant effect by probiotics on the reduction of uremic toxins in pediatric dialysis patients. Therefore, studies for other medical intervention to reduce uremic toxins are also necessary in pediatric patients on dialysis. SN - 1738-1061 UR - https://www.unboundmedicine.com/medline/citation/23646054/p_Cresyl_sulfate_and_indoxyl_sulfate_in_pediatric_patients_on_chronic_dialysis_ L2 - https://kjp.or.kr/journal/view.php?doi=10.3345/kjp.2013.56.4.159 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.